Welcome to our dedicated page for Meiragtx Holdings Plc SEC filings (Ticker: MGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MeiraGTx Holdings plc filings document a clinical-stage genetic medicines company with ordinary shares listed on Nasdaq under MGTX. The company’s 8-K reports cover material definitive agreements, collaboration and license arrangements, asset purchases for genetic-medicine programs, Regulation FD clinical disclosures, operating and financial results, and amendments to note and warrant financing arrangements.
Its proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related corporate-governance disclosures. The filing record also documents capital structure, subsidiary guarantor arrangements, risk-oriented clinical and regulatory disclosures, and program-specific matters involving AAV-hAQP1, AAV-AIPL1, RPGR-related X-linked retinitis pigmentosa assets, and riboswitch technology.
MeiraGTx Holdings plc CFO & COO Richard Giroux reported equity award activity involving restricted share units and ordinary shares. On February 21, 2026, one-quarter of previously granted restricted share units vested, converting 60,000 restricted share units into 60,000 ordinary shares at a stated price of $0.00 per share. To cover taxes due upon vesting, 31,726 ordinary shares were withheld at $7.45 per share as a tax-withholding disposition. Following these transactions, Giroux directly held 1,027,530 ordinary shares, with additional indirect holdings of 5,152 ordinary shares held by his spouse and 85,000 ordinary shares held by Aigle Healthcare Partners III LLC.
MeiraGTx Holdings plc President and CEO Alexandria Forbes reported equity award activity involving restricted share units and ordinary shares. On February 21, 2026, 62,500 restricted share units vested and were converted into 62,500 ordinary shares at a stated price of $0.0000 per share. A separate entry shows 33,048 ordinary shares withheld at $7.45 per share to cover taxes due upon vesting of the award, rather than an open-market sale. Following these transactions, Forbes directly holds 1,511,695 ordinary shares of MeiraGTx.
MeiraGTx Holdings plc received an updated ownership report from a Prosight investment group on Ordinary Shares. The group, including Prosight Management, Prosight Fund, Prosight Plus Fund, Prosight Partners and W. Lawrence Hawkins, reports beneficial ownership of 3,211,788 Ordinary Shares, or 4.0% of the company, as of the event date. This percentage is calculated using 80,490,889 Ordinary Shares outstanding as of October 28, 2025. The reporting persons certify the shares are not held to change or influence control of MeiraGTx and are reported on a passive Schedule 13G/A basis.
MeiraGTx Holdings plc disclosed that investment firm Rubric Capital Management LP and David Rosen have filed a Schedule 13G reporting beneficial ownership of 6,175,331 Ordinary Shares, equal to 7.90% of the company’s ordinary shares outstanding as of year-end 2025.
The filing shows Rubric Capital and Rosen share both voting and dispositive power over these shares, which are held through Rubric-managed funds, including Rubric Capital Master Fund LP. They state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of MeiraGTx.
MeiraGTx Holdings plc’s Chief Medical Officer, Robert K. Zeldin, reported equity compensation activity on January 17, 2026. One-half of a prior grant of restricted share units vested, resulting in 35,000 restricted share units converting into the same number of ordinary shares at an exercise price of $0.
To cover taxes due on this vesting, 13,951 ordinary shares were automatically withheld and disposed of at a price of $7.42 per share. After these transactions, Zeldin directly beneficially owned 168,340 ordinary shares of MeiraGTx. The filing indicates these are routine equity award vesting and tax-withholding events rather than open-market purchases or discretionary sales.
MeiraGTx Holdings plc reported an insider equity transaction for its General Counsel and Secretary, Robert J. Wollin. On January 17, 2026, one-half of a prior award of restricted share units vested, resulting in 50,000 ordinary shares being issued upon conversion of the vested units at an exercise price of $0 per share. In a related transaction, 27,206 ordinary shares were withheld at $7.42 per share to cover taxes due on the vesting. Following these transactions, Wollin directly owned 52,076 ordinary shares of MeiraGTx.
MeiraGTx Holdings plc Chief Development Officer Stuart Naylor reported equity compensation activity on January 17, 2026. One-half of a prior grant of restricted share units vested, converting 75,000 restricted share units into 75,000 ordinary shares at an exercise price of $0. To cover taxes due upon vesting, 35,250 ordinary shares were withheld at a value of $7.42 per share. After these transactions, Naylor directly owned 682,916 ordinary shares of MeiraGTx and continued to hold 75,000 restricted share units that remain outstanding.
MeiraGTx Holdings plc officer reports RSU vesting and related share withholding. On January 17, 2026, CFO & COO Richard Giroux had 310,000 restricted share units vest, each converting into one ordinary share at an exercise price of $0. In a separate transaction the same day, 163,916 ordinary shares were disposed of at $7.42 per share to cover taxes due upon vesting. Following these transactions, Giroux directly beneficially owned 999,256 ordinary shares, with additional indirect holdings of 5,152 shares through a spouse and 85,000 shares through Aigle Healthcare Partners III LLC.
MeiraGTx Holdings plc insider Alexandria Forbes, the President and CEO, reported equity award vesting and related tax withholding. On January 17, 2026, 310,000 restricted share units vested from a grant originally made on January 17, 2024, with each unit converting into one ordinary share upon vesting.
To cover taxes on this vesting, 163,916 ordinary shares were withheld at a price of $7.42 per share. After these transactions, Forbes directly holds 1,482,243 ordinary shares of MeiraGTx and 310,000 restricted share units as derivative securities.
MeiraGTx Holdings plc Chief Medical Officer Robert K. Zeldin filed a Form 4 showing routine equity compensation activity. On January 7, 2026, 17,500 restricted share units granted on January 7, 2022 vested, with each unit converting into one ordinary share. To cover taxes on this vesting, 6,729 ordinary shares were withheld at a price of $7.73 per share rather than being sold in the open market.
After these transactions, Zeldin directly beneficially owned 147,291 ordinary shares of MeiraGTx. The filing reflects compensation-related vesting and associated tax withholding rather than discretionary market buying or selling.